Follow us...

 

Search News Archives

News Channels

 

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

World's First Synthetic Corneal Epithelial Transplant Approved for Clinical Trials

publication date: Oct 8, 2015
 | 
author/source: Electrospinning Company

The first clinical trials introducing electrospinning technology to address the loss of vision due to scarring of the cornea have been approved to take place in the LVPrasad eye clinic in India.

electrospinning Membranes used in these initial trials will be produced by the UK’s Electrospinning Company that specialise in manufacturing materials for use in regenerative medicine.

After 4 years of collaboration between organisations in India and the UK, led by the university of Sheffield, the Electrospinning Company can announce trials will begin in India in Autumn 2015, involving 10 patients whom have sustained an eye injury, primarily through either industrial or cooking accidents, causing chemical burns.

The award winning company is now seeking investment of £450,000 through equity crowdfunding platform SyndicateRoom. 

Using this leading technology, patients will be treated by using a minute piece of tissue from their unaffected eye, which is cut into between 8 and 10 pieces containing corneal stem cells. This is then lightly attached to a synthetic biodegradable membrane, which is placed onto the damaged eye. This membrane, made of the same material as dissolvable sutures, provides a secure surface for new corneal cells to grow out from the stem cells present in the tissue pieces. 

After a few weeks, this membrane dissolves, leaving the new cells securely attached to the eye. The new corneal surface is formed to replace the scarred surface and will dramatically improve patient’s vision. The technique offers an affordable and effective way of treating damage to the cornea, which is one of the major causes leading to blindness.

Corneal blindness affects around 8-10 million people in India alone and of these, around 10-15% could benefit from this new treatment once established. Currently, patients with extensive scarring of the cornea can only be treated in specialist centres where cells from the unaffected eye are cultured and grafted back to the scarred eye using a human amniotic membrane taken from a donated placenta. While the success rates are high, there are less than 12 centres in the world and only 3 in India offering this technology.

The new technique uses a synthetic membrane, which will be available as a sterile packaged product without any risk of disease transmission. This not only makes it safer and cheaper but also more readily available than relying on donated amniotic membranes, which can only be acquired if surgeons have access to Tissue Banks stocking these membranes. 

Treating corneal blindness is a particular problem in the developing world, where there are high instances of chemical or accidental damage to the eye. More complex treatments such as transplants or amniotic membrane grafts are not available to large proportions of the population due to the high costs and lack of appropriate healthcare facilities.

The research is funded by the Wellcome Trust through an Affordable Healthcare in India Award, the objective of which is to fund translational research projects to deliver safe, effective and accessible healthcare products for India, and potentially other developing markets.

Dr Stephen Caddick, Director of Innovations at the Wellcome Trust, said: “India has some of the highest levels of preventable blindness in the world. Yet limited access to affordable healthcare means that the best treatments are often unavailable to those in greatest need. By supporting the development of high-quality, affordable technologies, we intend to help more people in low and middle-income countries to benefit from the latest medical advances.”

When asked what motivates her to take this company from strength to strength, CEO Ann Kramer commented that her driving force was:

“The potential to contribute to healthcare innovations that offer a step change in affordability, availability and simplicity in the new field of regenerative devices.”


more about electrospinning company


 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners